Pemoline and urinary excretion of catecholamines and indoleamines in children with attention deficit disorder.
To test the hypothesis that any change in urinary noradrenergic excretion accompanies drug-induced improvement in attention deficit disorder with hyperactivity, the authors gave pemoline (mean dose, 2.9 mg/kg of body weight) to 11 boys with this disorder in a 4-week open trial. Pemoline administration improved behavior but did not significantly change urinary catecholamine excretion. Serotonin excretion was unchanged, but phenylethylamine (PEA) and 5-hydroxyindoleacetic acid (5-HIAA) were significantly decreased. Clinical responders and nonresponders did not differ with respect to baseline urinary monoamine excretion or change in PEA and 5-HIAA excretion.
A J
AJ
Zametkin
M
M
Linnoila
F
F
Karoum
R
R
Sallee
D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology / Q000652:urine; D002648:Child; D003913:Dextroamphetamine / Q000627:therapeutic use; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine*; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use; D009638:Norepinephrine / Q000378:metabolism; D010389:Pemoline / Q000627:therapeutic use*; D010627:Phenethylamines / Q000652:urine*; D012701:Serotonin / Q000652:urine*
D010627:Phenethylamines; D008774:Methylphenidate; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D010389:Pemoline; D003913:Dextroamphetamine; D009638:Norepinephrine